The US Federal Trade Commission (FTC) revealed on Friday that it has filed an amicus brief explaining that pharmaceutical maker Teva Pharmaceutical Industries (NYSE: TEVA) has improperly listed patents in the Food and Drug Administration’s (FDA) Orange Book and urged the court to order those listings removed.
Improper Orange Book listings can harm competition by delaying the entry of cheaper generic products, according to the FTC’s brief.
The FTC’s amicus brief relates to a case brought by Israel-headquartered Teva against US drugmaker Amneal Pharmaceuticals (NYSE: AMRX) after Amneal sought FDA approval to bring a generic version of asthma inhaler ProAir HFA to market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze